Plutus Capital Management Acquires 7.75% Stake in Ganga Pharmaceuticals Through Warrant Conversion

Ganga Pharmaceuticals Ltd has seen a significant change in its shareholding structure as Plutus Capital Management LLP acquired a substantial stake in the company. The investment firm secured a 7.75% stake through the conversion of convertible warrants into equity shares.

Transaction Details

On July 17, Plutus Capital Management LLP converted its warrants into 375,000 equity shares of Ganga Pharmaceuticals Ltd. This transaction marked Plutus Capital's entry into the company's shareholding structure, as they held no shares prior to this acquisition.

Impact on Share Capital

The warrant conversion has led to a notable increase in Ganga Pharmaceuticals' total equity share capital:

Metric	Before Conversion	After Conversion
Total Equity Share Capital	Rs. 4.84 crore	Rs. 5.91 crore
Number of Equity Shares	48.37 lakh	59.12 lakh
Face Value per Share	Rs. 10	Rs. 10

Shareholding Structure

Plutus Capital Management LLP now holds 375,000 shares, representing 7.75% of the total share capital and 6.34% of the diluted share capital.
The acquisition was made through preferential allotment, as confirmed by the LODR disclosure.
Plutus Capital Management is not part of the promoter group of Ganga Pharmaceuticals Ltd.

Regulatory Compliance

The transaction was reported in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Plutus Capital Management LLP submitted the required disclosure to BSE Limited on July 31.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-100.00%	0.0%	0.0%	-100.00%	-100.00%	-100.00%

Acquisition Details

Plutus Capital Management LLP, a non-promoter entity, has acquired a 7.75% stake in Ganga Pharmaceuticals. The acquisition was completed through the conversion of convertible warrants into equity shares. Here are the key details of the transaction:

Shares Acquired: 3,75,000
Mode of Acquisition: Preferential allotment
Date of Allotment: July 17, 2025
Percentage Stake: 7.75% of the total share capital (6.34% of the diluted share capital)

Impact on Share Capital

The acquisition has led to an increase in Ganga Pharmaceuticals' equity share capital:

Description	Value
Before Acquisition	Rs. 4,83,65,000 (48,36,500 shares)
After Acquisition	Rs. 5,91,15,000 (59,11,500 shares)

Disclosure and Compliance

In compliance with SEBI regulations, Plutus Capital Management LLP has made the necessary disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was filed on July 31, 2025, providing details of the acquisition to both BSE Limited and Ganga Pharmaceuticals.

About the Acquirer

Plutus Capital Management LLP, represented by Siddhant Kabra (DIN: 07470463), is not part of the promoter group of Ganga Pharmaceuticals. Prior to this transaction, Plutus Capital held no shares in the company.

Market Information

Ganga Pharmaceuticals' shares are listed on BSE Limited. Investors and market participants are advised to take note of this significant change in the company's shareholding pattern.

This acquisition marks a notable development for Ganga Pharmaceuticals, potentially influencing its future strategic decisions and market perception.